Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: Current issues and new agents

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 457-468

  Strasfeld, Lynne ^a   Weinstock, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antifungals; Prophylaxis; Stem cell transplant; Voriconazole

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIGOXIN; ECHINOCANDIN; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; PHENYTOIN; POSACONAZOLE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GRAFT INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; INFECTION RISK; LIVER DYSFUNCTION; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; REVIEW; RISK FACTOR; VISUAL DISORDER;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745225428     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.457     Document Type: Review

References (76)

1. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J. Infect. Dis. 164, 731-740 (1991).
2. Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32, 358-366 (2001).
3. Anaissie EJ, Kuchar RT, Rex JH et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin. Infect. Dis. 33, 1871-1878 (2001).
4. Anaissie EJ, Stratton SL, Dignani MC et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin. Infect. Dis. 34, 780-789 (2002).
5. Anaissie EJ, Stratton SL, Dignani MC et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin. Infect. Dis. 35, e86-e88 (2002).
6. Offidani M, Corvatta L, Olivieri A et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant. 24, 1079-1087 (1999).
7. Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant. 28, 265-271 (1996).
8. Auner HW, Sill H, Mulabecirovic A et al. Infectious complications after autologous haematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann. Hematol. 81, 374-377 (2002).
9. Jantunen E, Salonen J, Juvonen E et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur. J. Haematol. 73, 174-178 (2004).
10. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mold infections in haematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917 (2002).
11. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 19, 801-808 (1997).
12. Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175, 1459-1466 (1997).
13. Hagen EA, Stern H, Porter D et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin. Infect. Dis. 36, 9-15 (2003).
14. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic haematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102, 827-933 (2003).
15. Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol. 116, 475-482 (2002).
16. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002).
17. Singh N. Interactions between viruses in transplant recipients. Clin. Infect. Dis. 40, 430-436 (2005).
18. Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39, 3254-3259 (2001).
19. Pfaller MA, Diekema DJ, Messer SA et al. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and E test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J. Clin. Microbiol. 41, 1440-1446 (2003).
20. Wingard JR, Merz WG, Rinaldi MG et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37, 1847-1849 (1993).
21. Marr KA, White TC, van Burik JA et al. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25, 908-910 (1997).
22. CDC; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among haematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 6, 659-713 (2000).
23. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326, 845-851 (1992).
24. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective randomized, double-blind study. J. Infect. Dis. 171, 1545-1552 (1995).
25. Marr KA, Siedel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96, 2055-2061 (2000).
26. Antifungal drugs. Treat Guidel. Med. Lett. 3(30), 7-14 (2005).
27. Micafungin (Mycamine®) for fungal infections. Med. Lett. 47, 51-52 (2005).
28. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630-637 (2003).
29. Denning DW. Echinocandin antifungal drugs. Lancet 362, 1142-1151 (2003).
30. Marr KA, Crippa F, Leisenring W et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 12(5), 552-559 (2006).
31. Marty FM, Laury CM, Cutler CS. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 36, 2708-2709 (2004).
32. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41, 2326-2332 (1997).
33. Bowman JC, Hicks PS, Kurtz MB et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46, 3001-3012 (2002).
34. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin. Infect. Dis. 42, 1171-1178 (2006).
35. Powles MA, Liberator P, Anderson J et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. 42, 1985-1989 (1998).
36. van Burik JAH, Ratanatharathorn V, Stepan D et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing haematopoietic stem cell transplantation. Clin. Infect. Dis. 39, 1407-1416 (2004).
37. De Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. 39, 842-849 (2004).
38. Trenschel R, Ditschkowski M, Elmaagacgli AH et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant. 35, 583-586 (2005).
39. Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis. 6, 110-116 (2004).
40. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant. 34, 13-20 (2004).
41. Martino R, Nomdedeu J, Altes A. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant. 13, 265-269 (1994).
42. Kruger WH, Russmann B, de Wit M et al. Haematopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol. 113, 104-108 (2005).
43. Mehta P, Augustson B, Krishnamurthy S et al. Successful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection. Bone Marrow Transplant. 34, 825-826 (2004).
44. Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant. 33, 943-948 (2004).
45. Cornely O, Maertens J, Winston D et al. Posaconazole vs standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: results of a randomized, multicenter trial. Program and abstracts of the 47th American Society of Hematology. GA, USA, Abstract 1844 (2005).
46. Cornely OA, Maertens J, Winston D et al. Posaconazole vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome: impact on mortality. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, Abstract M-722b (2005).
47. Diekema DJ, Messer SA, Hollis RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41, 3623-3626 (2003).
48. Jantunen E, Nihtinen A, Volin L et al. Candidemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. Bone Marrow Transplant. 34, 891-895 (2004).
49. Marr KA. Issues in the design of fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39(Suppl. 4), S170-S175 (2004).
50. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind, placebo-controlled study. Bone Marrow Transplant. 23, 163-168 (1999).
51. Tollemar J, Ringden O, Andersson B et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 12, 577-582 (1993).
52. Barrett JP, Vardulaki KA, Conlon C. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther. 25, 1295-1320 (2003).
53. Winston DJ, Maziarz RT, Pranatharthi H et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann. Intern. Med. 138, 705-713 (2002).
54. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103, 1527-1533 (2004).
55. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann. Hematol. 71, 311-312 (1995).
56. Gillies J, Hung K, Fitzsimons E et al. Severe vincristine toxicity in combination with itraconazole. Clin. Lab. Haematol. 20, 123-124 (1998).
57. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole vs. fluconazole for the prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: results of a multicenter trial. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, Abstract M-716 (2005).
58. Buell DB, Kovanda D, Drake T et al. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, Abstract M-719 (2005).
59. Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother. 49, 1331-1336 (2005).
60. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191, 1350-1360 (2005).
61. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 26, 950-952 (2004).
62. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis. 39, 584-587 (2004).
63. Imhof A, Balajee SA, Fredricks DN et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39, 743-746 (2004).
64. Vigouroux S, Morin O, Moreau P et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin. Infect. Dis. 40, e35-e37 (2005).
65. Girmenia C, Moleti ML, Micozzi A et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J. Clin. Microbiol. 43, 5395-5396 (2005).
66. Safdar A, O'Brien S, Kouri IF. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant. 34, 467-468 (2004).
67. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351, 1391-1402 (2004).
68. Pavie J, Lacroix C, Hermoso DG et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J. Clin. Microbiol. 43, 4902-4904 (2005).
69. Alexander BD, Schell WA, Miller JL et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80, 868-871 (2005).
70. Kauffman CA. Zygomycosis: re-emergence of an old pathogen. Clin. Infect. Dis. 39, 588-590 (2004).
71. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41, 634-653 (2005).
72. Torres HA, Hachem RY, Chemaly RF et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5, 775-785 (2005).
73. Tobon AM, Arango M, Fernandez D et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36, 1488-1491 (2003).
74. van Burik JA, Hare RS, Solomon HF et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42, e61-e65 (2006).
75. Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39, 797-802 (2004).
76. Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97, 1025-1032 (2003).